Growth Metrics

Oruka Therapeutics (ORKA) Cash from Investing Activities (2010 - 2026)

Oruka Therapeutics' quarterly Cash from Investing Activities came in at -$14.4 million in Q1 2026, down 133.68% year-on-year from $42.9 million in Q1 2025, and up 34.44% quarter-over-quarter from -$22.0 million in Q4 2025.

Oruka Therapeutics has reported Cash from Investing Activities for 15 years, with the latest figure at -$14.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities fell 133.68% year-over-year to -$14.4 million; the trailing twelve-month figure through Mar 2026 stood at -$154.0 million (up 46.37% YoY), and the FY2025 full-year result was -$96.7 million, up 70.69% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$14.4 million, up from -$22.0 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $42.9 million in Q1 2025, with the low at -$330.0 million in Q4 2024.
  • Average Cash from Investing Activities over 4 years is -$55.2 million, with a median of -$7.3 million recorded in 2024.
  • Peak annual rise in Cash from Investing Activities reached 93.33% in 2025, while the deepest fall reached 71507.6% in 2025.
  • Tracing ORKA's Cash from Investing Activities over 4 years: stood at -$2000.0 in 2022, then plunged by 16497700.0% to -$330.0 million in 2024, then jumped by 93.33% to -$22.0 million in 2025, then jumped by 34.44% to -$14.4 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$14.4 million (Q1 2026), -$22.0 million (Q4 2025), and -$122.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.89 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -25.54 Mn
10 Oruka Therapeutics 3.04 Bn 2.65 Bn - -14.44 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -14.44 Mn
Mar 31, 2026 -14.44 Mn
Dec 31, 2025 -22.02 Mn
Dec 31, 2025 -22.02 Mn
Sep 30, 2025 -122.45 Mn
Sep 30, 2025 -122.45 Mn
Jun 30, 2025 4.86 Mn
Jun 30, 2025 4.86 Mn
Mar 31, 2025 42.87 Mn
Mar 31, 2025 42.87 Mn
Dec 31, 2024 -329.96 Mn
Dec 31, 2024 -329.96 Mn
Sep 30, 2024 -171,000.00
Sep 30, 2024 -171,000.00
Mar 31, 2022 -2,000.00
Mar 31, 2022 -2,000.00
Dec 31, 2021 -7,000.00
Dec 31, 2021 -7,000.00
Sep 30, 2021 -14,000.00
Sep 30, 2021 -14,000.00
Jun 30, 2021 -16,000.00
Jun 30, 2021 -16,000.00
Mar 31, 2021 -6,000.00
Mar 31, 2021 -6,000.00
Dec 31, 2020 -13,000.00
Dec 31, 2020 -13,000.00
Jun 30, 2020 -3,000.00
Jun 30, 2020 -3,000.00
Mar 31, 2020 -3,000.00
Mar 31, 2020 -3,000.00
Dec 31, 2019 -2,000.00
Dec 31, 2019 -2,000.00
Sep 30, 2018 -3,000.00
Sep 30, 2018 -3,000.00
Mar 31, 2018 3.05 Mn
Mar 31, 2018 3.05 Mn
Dec 31, 2017 4.75 Mn
Dec 31, 2017 4.75 Mn
Sep 30, 2017 -932,000.00
Sep 30, 2017 -932,000.00
Jun 30, 2017 6.10 Mn
Jun 30, 2017 6.10 Mn
Mar 31, 2017 3.01 Mn
Mar 31, 2017 3.01 Mn
Dec 31, 2016 3.15 Mn
Dec 31, 2016 3.15 Mn
Sep 30, 2016 -2.55 Mn
Sep 30, 2016 -2.55 Mn
Jun 30, 2016 -11.81 Mn
Jun 30, 2016 -11.81 Mn
Mar 31, 2016 -5.20 Mn
Mar 31, 2016 -5.20 Mn
Dec 31, 2015 -2,000.00
Dec 31, 2015 -2,000.00
Sep 30, 2015 -2,000.00
Sep 30, 2015 -2,000.00
Jun 30, 2015 -5,000.00
Jun 30, 2015 -5,000.00
Mar 31, 2015 -2,000.00
Mar 31, 2015 -2,000.00
Dec 31, 2014 -14,000.00
Dec 31, 2014 -14,000.00
Dec 31, 2013 -4,000.00
Dec 31, 2013 -4,000.00
Sep 30, 2013 -11,000.00
Sep 30, 2013 -11,000.00
Jun 30, 2013 -8,000.00
Jun 30, 2013 -8,000.00
Mar 31, 2013 -9,000.00
Mar 31, 2013 -9,000.00
Dec 31, 2011 5,000.00
Dec 31, 2011 5,000.00
Sep 30, 2011 1,000.00
Sep 30, 2011 1,000.00
Dec 31, 2010 261,000.00
Dec 31, 2010 261,000.00